0000000000489558

AUTHOR

H Pfeiffer-vornkahl

showing 1 related works from this author

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with H…

2016


 
 
 
 
 
 Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy.
 Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed.
 Resu…

MaleTime Factors030508 substance abuseHepacivirusmedicine.disease_causeGastroenterologyTelaprevirPolyethylene Glycolschemistry.chemical_compound0302 clinical medicineRisk FactorsGermanyOdds RatioAged 80 and overSmokingGastroenterologyHepatitis CMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemale0305 other medical scienceViral loadOligopeptidesmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeProlineHepatitis C virusAlpha interferonAntiviral Agents03 medical and health sciencesYoung AdultBoceprevirInternal medicineRibavirinmedicineHumansProtease inhibitor (pharmacology)Protease InhibitorsAgedbusiness.industryRibavirinInterferon-alphamedicine.diseaseVirology030227 psychiatryLogistic ModelschemistryMultivariate AnalysisbusinessJournal of gastrointestinal and liver diseases : JGLD
researchProduct